Friday November 27 2009 | Biotechnology feed | All feeds
|
|
Biovertis AG
Download detailed PDF Members: Biovertis is a privately-held, Austrian biotechnology company focusing on the discovery and development of novel classes of small molecule antibacterials. The antibiotics market is currently dominated by drug classes that have been in use for decades. However, an alarming rise in pathogens that are resistant to these types of drugs has created an urgent, unmet medical need in this field. With an advanced pipeline of proprietary compounds, all of which are characterized by a novel therapeutic mode of action, Biovertis addresses exactly this demand. In addition, the Company runs a highly efficient drug discovery process based on structural biology yielding further novel antibiotic classes that recognize new therapeutic targets. Biovertis' team has dedicated drug development expertise to take its candidates efficiently forward through clinical trials. Oxaquin, the most advanced candidate, is scheduled to enter clinical development in mid-2006.
This page has been viewed 585 times since April 2007, the link to the organisation's website has been followed 113 times Recent Search Terms used to find this page: biovertis vienna tel | biovertis AG | Biovertis AG | Biovertis AG | Biovertis AG | Biovertis AG | biovertis | biovertis | biovertis ag | biovertis ag | . Search for more companies in Vienna This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Biovertis AG | |||||||||||||||||||||||||||||||||||||||||||||||||
|